EdgeMarket › What Eversept Partners, Lp reported owning
What Eversept Partners, Lp reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
1.9BPositions
120Quarter
2026-03-31Shown below
50largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| UTHR UNITED THERAPEUTICS Corp | 156.7M | 8.3% | 264.3K | 513.12 | +67.4% |
| ABVX Abivax S.A. | 104.0M | 5.5% | 934.4K | 114.95 | +59.9% |
| GSK GSK plc | 98.5M | 5.2% | 1.8M | 52.41 | +30.8% |
| VERA Vera Therapeutics, Inc. | 87.4M | 4.6% | 2.2M | 32.27 | +46.0% |
| NTRA Natera, Inc. | 76.9M | 4.1% | 384.7K | 332.03 | +106.7% |
| SNDX Syndax Pharmaceuticals Inc | 67.4M | 3.6% | 2.9M | 19.65 | +24.8% |
| CLDX Celldex Therapeutics, Inc. | 56.7M | 3.0% | 1.8M | 40.38 | +93.3% |
| PCVX Vaxcyte, Inc. | 53.7M | 2.8% | 924.2K | 62.62 | +100.3% |
| BKD Brookdale Senior Living Inc. | 48.8M | 2.6% | 3.6M | 11.80 | +61.4% |
| IONS IONIS PHARMACEUTICALS INC | 47.5M | 2.5% | 632.1K | 59.74 | +39.5% |
| HCA HCA Healthcare, Inc. | 37.5M | 2.0% | 79.2K | 429.19 | +4.6% |
| WELL WELLTOWER INC. | 35.8M | 1.9% | 181.0K | 239.22 | +44.1% |
| DOC HEALTHPEAK PROPERTIES, INC. | 32.5M | 1.7% | 2.0M | 21.40 | +24.3% |
| PODD INSULET CORP | 30.1M | 1.6% | 143.5K | 148.16 | -55.5% |
| BCRX BIOCRYST PHARMACEUTICALS INC | 28.9M | 1.5% | 3.0M | 9.55 | +14.0% |
| GERN GERON CORP | 28.1M | 1.5% | 18.8M | 1.52 | +9.4% |
| OHI OMEGA HEALTHCARE INVESTORS INC | 25.7M | 1.4% | 585.7K | 46.61 | +11.4% |
| LQDA Liquidia Corp | 25.6M | 1.3% | 677.4K | 68.62 | +150.9% |
| CYH COMMUNITY HEALTH SYSTEMS INC | 25.5M | 1.3% | 8.7M | 3.01 | +11.1% |
| AVTR Avantor, Inc. | 23.3M | 1.2% | 3.0M | 14.46 | +12.3% |
| QGEN QIAGEN N.V. | 21.8M | 1.2% | 545.3K | 44.07 | -10.4% |
| EHC Encompass Health Corp | 18.8M | 1.0% | 194.1K | 120.31 | -2.6% |
| LLY ELI LILLY & Co | 17.5M | 0.9% | 19.0K | 1,255.40 | +78.0% |
| TVTX Travere Therapeutics, Inc. | 16.1M | 0.9% | 542.6K | 65.71 | +265.7% |
| CTMX CytomX Therapeutics, Inc. | 15.0M | 0.8% | 3.2M | 3.28 | +66.5% |
| RGEN REPLIGEN CORP | 14.2M | 0.8% | 120.8K | 181.13 | +49.0% |
| BBNX Beta Bionics, Inc. | 14.2M | 0.7% | 1.4M | 19.05 | +24.5% |
| VRDN Viridian Therapeutics, Inc.\DE | 14.0M | 0.7% | 713.3K | 24.29 | +33.9% |
| ARQT Arcutis Biotherapeutics, Inc. | 13.6M | 0.7% | 576.6K | 25.08 | +58.8% |
| ARDX ARDELYX, INC. | 13.4M | 0.7% | 2.2M | 3.89 | -35.1% |
| LTC LTC PROPERTIES INC | 11.9M | 0.6% | 321.0K | 40.27 | +11.1% |
| BMRN BIOMARIN PHARMACEUTICAL INC | 11.7M | 0.6% | 207.8K | 66.70 | +15.1% |
| CHE CHEMED CORP | 11.7M | 0.6% | 31.1K | 540.57 | +18.7% |
| PHVS Pharvaris N.V. | 11.5M | 0.6% | 407.0K | 36.27 | +57.7% |
| PNTG Pennant Group, Inc. | 9.5M | 0.5% | 312.2K | 38.88 | +54.5% |
| NAMS NewAmsterdam Pharma Co N.V. | 9.1M | 0.5% | 285.8K | 27.87 | +14.6% |
| PALI PALISADE BIO, INC. | 8.7M | 0.5% | 5.0M | 2.10 | +191.7% |
| MRNA Moderna, Inc. | 8.1M | 0.4% | 159.7K | 145.13 | +439.7% |
| VKTX Viking Therapeutics, Inc. | 7.8M | 0.4% | 239.1K | 33.89 | +31.9% |
| ICLR ICON PLC | 7.6M | 0.4% | 68.7K | 172.23 | -4.4% |
| XENE Xenon Pharmaceuticals Inc. | 7.5M | 0.4% | 129.6K | 60.77 | +61.5% |
| RVTY REVVITY, INC. | 7.4M | 0.4% | 84.9K | 124.75 | +36.0% |
| AGIO AGIOS PHARMACEUTICALS, INC. | 6.8M | 0.4% | 200.0K | 33.09 | -10.1% |
| GPCR Structure Therapeutics Inc. | 6.7M | 0.4% | 138.0K | 49.09 | +164.4% |
| TECH BIO-TECHNE Corp | 6.6M | 0.3% | 125.9K | 72.32 | +33.1% |
| GKOS GLAUKOS Corp | 6.5M | 0.3% | 60.2K | 184.89 | +103.3% |
| THC TENET HEALTHCARE CORP | 5.6M | 0.3% | 29.5K | 280.77 | +54.3% |
| MDGL MADRIGAL PHARMACEUTICALS, INC. | 5.2M | 0.3% | 10.0K | 516.74 | +31.9% |
| ISRG INTUITIVE SURGICAL INC | 5.1M | 0.3% | 11.1K | 378.81 | -21.2% |
| unmapped CUSIP 29664W105 | 4.8M | 0.3% | 1.7M | — | — |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →